Pfizer deal probably 'would have fallen apart': AZ CEO
November 28, 2014 at 01:01 AM EST
Pfizer's attempt to gain control of U.K. pharmaceutical company AstraZeneca through a £69.4 billion ($110 billion) bid in May would have run aground on changes to U.S. tax inversion laws, the chief executive of AstraZeneca has told CNBC.
